Clinical Trial Update: Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a busulfan/melphalan/fludarabine conditioning regimen with T-cell depleted allogeneic hematopoietic stem cell transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Donor Lymphocyte Infusions
• Fludarabine (Fludarabine)
• Melphalan (Melphalan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-02